{"filing":{"accession_number":"0001840199-26-000078","cik":"0001840199","ticker":"WALDW","company_name":"Waldencast plc","form":"6-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"wald6-k_obagitransactioncl.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840199/000184019926000078/wald6-k_obagitransactioncl.htm"},"events":[{"id":22243,"run_id":20112,"accession_number":"0001840199-26-000078","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The exhibit announces completion of the sale of Obagi Medical to Bridgepoint for up to $460 million, a material disposition that fundamentally reshapes Waldencast's business portfolio. The transaction includes repayment of all outstanding senior term loan debt and departure of three executives (founders Michel Brousset and Hind Sebti, plus CFO Manuel Manfredi) to lead the divested business, with Felipe Dutra assuming principal executive and financial officer roles. This is a completed M\u0026A transaction (Item 1.02 / 2.01 equivalent) that materially affects the registrant's capital structure and strategic direction.","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-07-30","form":"6-K","submitted_at":null,"items":[{"id":22133,"accession_number":"0001840199-26-000078","item_number":"EX-99.1","item_title":"waypoint-closingpressrelea.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces completion of the sale of Obagi Medical to Bridgepoint for up to $460 million, a material disposition that fundamentally reshapes Waldencast's business portfolio. The transaction includes repayment of all outstanding senior term loan debt and departure of three executives (founders Michel Brousset and Hind Sebti, plus CFO Manuel Manfredi) to lead the divested business, with Felipe Dutra assuming principal executive and financial officer roles. This is a completed M\u0026A transaction (Item 1.02 / 2.01 equivalent) that materially affects the registrant's capital structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:20:24.977958+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22133,"accession_number":"0001840199-26-000078","item_number":"EX-99.1","item_title":"waypoint-closingpressrelea.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces completion of the sale of Obagi Medical to Bridgepoint for up to $460 million, a material disposition that fundamentally reshapes Waldencast's business portfolio. The transaction includes repayment of all outstanding senior term loan debt and departure of three executives (founders Michel Brousset and Hind Sebti, plus CFO Manuel Manfredi) to lead the divested business, with Felipe Dutra assuming principal executive and financial officer roles. This is a completed M\u0026A transaction (Item 1.02 / 2.01 equivalent) that materially affects the registrant's capital structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:20:24.977958+00:00","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-07-30"}]}